Latest stories on RZLT
Rezolute: Initiating At Sell Despite Attempts To Rescue Ersodetug Following sunRIZE Upset
Seeking Alpha28 · bearishproduct/pr
Rezolute says late-stage trial data for lead asset remains under FDA review
Seeking Alpha38 · neutralgeneral
Rezolute provides update on FDA review of sunRIZE study
The Fly59 · neutralgeneral
Rezolute Provides Update on FDA Review of its Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism
StockTitan34 · bearishproduct/pr
Rezolute Provides Update on FDA Review of its Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism
GlobeNewswire34 · bearishproduct/pr
Rezolute to Participate in Upcoming Investor Conferences
GlobeNewswire56 · neutralgeneral
Rezolute to Participate in Upcoming Investor Conferences
Business Insider56 · neutralgeneral
H.C. Wainwright reiterates Rezolute stock rating at buy, $5 target
Investing.com Analyst Ratings61 · neutralanalyst
Rezolute to Participate in the BTIG Virtual Biotechnology Conference
Business Insider55 · neutralgeneral
Rezolute Announces Four Presentations at the Upcoming Annual Meeting of the Endocrine Society | RZLT Stock News
StockTitan56 · neutralproduct/pr
Rezolute upgraded at Citizens after late-stage trial data for lead asset
Seeking Alpha63 · neutralanalyst
Rezolute rises after late-stage trial update
Seeking Alpha63 · neutralproduct/pr
Rezolute Reports Positive Phase 3 Data for Ersodetug
TipRanks73 · bullishproduct/pr
Rezolute Announces Positive Interim Data for its Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism | RZLT Stock News
StockTitan67 · bullishproduct/pr